Clinical Trial Update: Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing patient preference between cabazitaxel and docetaxel for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• Taxotere (docetaxel)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: COMPLETED